Data for (Study ST000677)

(Analysis AN001040)

Values for each metabolite have been scaled by dividing by the mean across all factors

Run Hierarchial cluster analysis on this study | Run Heatmap cluster analysis on this study

MetaboliteF1F2F3F4F5F6
CerP 34:1; [M-H]-@5.96 0.9913 1.4175 0.8214 1.0336 1.0288 0.7449
CL 66:1; [M-2H](2-)@6.29 0.8763 2.3076 0.6796 1.0602 0.9381 0.4283
CL 70:5; [M-2H](2-)@6.00 0.8145 1.5120 0.9885 1.1081 0.7474 0.9140
CL 74:3; [M-2H](2-)@7.01 0.7910 1.6489 1.2819 1.0359 0.7809 0.7933
FFA(16:0) 1.0627 1.2602 0.9711 0.9743 0.8621 0.9600
FFA(18:0) 1.0265 1.2437 1.0009 0.9929 0.8697 0.9484
FFA(18:1) 1.2471 1.1523 0.9288 0.9072 0.8859 0.9471
FFA(18:2) 1.1959 1.1177 0.8937 0.9003 0.8609 1.1029
FFA(20:0) 0.9251 1.1125 1.0570 1.0549 0.8464 1.0123
FFA(20:1) 1.3833 0.9959 0.8394 0.8943 0.8711 0.9743
FFA(20:2) 1.3092 1.0237 0.8879 0.8989 0.9049 0.9775
FFA(20:4) Arachidonic acid 1.2692 1.0444 0.7771 0.9314 0.7726 1.1476
FFA(22:0) 0.7450 0.6735 1.2612 1.0904 1.0242 1.1483
FFA(22:2) 1.2309 0.8411 0.9355 1.0154 0.8742 0.9308
FFA(22:3) 1.0606 0.8756 0.9235 1.0075 1.0117 1.0239
FFA(24:0) 0.8560 0.9037 1.0783 1.1175 0.7978 1.1320
FFA(24:1) 0.8752 0.6251 1.0577 1.0940 1.0738 1.0848
FFA(24:2) 1.0642 1.0010 0.8104 1.0578 0.8013 1.1040
FFA(24:3) 1.3145 0.8595 0.8280 1.0373 0.6442 1.0577
lysoPE 16:0; [M-H]-@1.69 0.9858 1.0526 0.9904 1.0269 0.7904 1.1371
lysoPE 18:0; [M-H]-@2.49 1.0368 1.0102 0.9094 1.0058 0.8144 1.1766
lysoPE 18:1; [M-H]-@1.86 0.8350 0.9242 1.1802 0.9642 0.8686 1.3654
lysoPE 18:2; [M-H]-@1.40 0.7744 0.9778 1.0441 1.0305 0.9842 1.2308
lysoPE 20:3; [M-H]-@1.68 0.7593 0.7559 0.9468 0.9912 1.4636 1.0763
lysoPE 20:4; [M-H]-@1.37 1.0663 0.7598 0.8644 1.0079 0.8944 1.2492
lysoPE 20:5; [M-H]-@1.13 0.6424 0.3780 0.8805 1.0836 1.1200 1.6561
lysoPE 22:4; [M-H]-@1.99 1.2588 1.1614 0.6466 0.7786 0.9966 1.3030
lysoPE 22:5; [M-H]-@1.58 1.0907 0.8085 1.0124 0.8472 0.9783 1.3766
lysoPE 22:6; [M-H]-@1.34 0.8121 0.5802 0.9672 0.9801 1.0692 1.5296
N-(15Z-tetracosenoyl)-sphing-4-enine; [M-H]-@8.52 1.0841 0.9058 1.1323 1.0542 0.8141 0.9217
N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.89 0.7901 0.6858 1.1784 1.0831 1.0785 1.0980
N-(tetracosanoyl)-sphing-4-enine; [M-H]-@8.96 0.9737 0.7442 1.1293 1.0599 0.9998 0.9797
PA 34:2; [M-H]-@6.38 0.9092 0.6999 1.4450 0.9221 1.1241 1.0822
PC 28:0; [M-Ac-H]-@5.41 0.9327 1.4247 1.2875 0.9925 0.8256 0.8068
PC 30:0; [M-Ac-H]-@6.11 1.0131 1.2371 0.9332 1.0995 0.7803 0.8565
PC 30:1; [M-Ac-H]-@5.55 0.9847 1.2458 0.9167 1.0679 0.9915 0.7622
PC 32:0; [M-Ac-H]-@6.77 1.0248 1.0086 0.8895 1.0654 0.8325 1.0497
PC 32:1; [M-Ac-H]-@6.25 0.9253 1.4932 0.6935 1.0064 1.0531 0.9071
PC 32:2; [M-Ac-H]-@5.74 0.9250 0.9025 1.4692 1.0461 0.9361 0.8086
PC 33:1; [M-Ac-H]-@6.59 0.9216 1.2314 0.8451 1.0045 1.0432 0.9998
PC 33:2; [M-Ac-H]-@6.11 0.9332 1.0757 1.1194 1.0548 0.7753 1.0559
PC 34:3; [M-Ac-H]-@5.93 1.0036 0.9991 1.0212 1.0674 0.8643 0.9601
PC 34:4; [M-Ac-H]-@5.62 0.8855 0.5148 1.5091 1.0898 1.0451 0.8820
PC 35:2; [M-Ac-H]-@6.70 1.0569 0.8234 1.1390 1.0429 0.9246 0.9245
PC 35:3; [M-Ac-H]-@6.26 0.7223 1.3847 0.9106 1.1145 0.7590 1.1474
PC 36:1; [M-Ac-H]-@7.50 0.9392 1.0732 0.8839 1.0468 0.9340 1.0666
PC 36:3; [M-Ac-H]-@6.54 1.0110 1.0985 1.0337 1.0371 0.8381 0.9725
PC 36:5; [M-Ac-H]-@5.84 0.8881 0.6652 0.8037 1.1297 0.9131 1.2876
PC 37:2; [M-Ac-H]-@7.38 0.9674 1.3548 1.0463 0.8691 1.0500 1.0316
PC 37:3; [M-Ac-H]-@6.86 0.9135 0.9281 0.7930 1.2851 0.9090 0.7270
PC 37:4; [M-Ac-H]-@6.68 1.0363 1.1681 0.8271 1.0829 0.9445 0.8168
PC 37:6; [M-Ac-H]-@5.92 0.7472 0.4983 1.4993 1.0583 1.1044 1.0981
PC 38:2; [M-Ac-H]-@7.64 1.1449 1.4439 0.7973 0.9722 0.8638 0.8471
PC 38:3; [M-Ac-H]-@7.26 1.0337 1.1320 0.8672 1.0321 0.9153 0.9656
PC 38:4; [M-Ac-H]-@6.89 1.2744 0.7455 0.7649 1.0739 0.7217 1.0664
PC 38:5; [M-Ac-H]-@6.52 1.0901 0.7328 0.8870 1.0614 0.8450 1.1451
PC 38:7; [M-Ac-H]-@5.65 0.8601 0.6090 1.0737 1.0500 1.1956 1.0858
PC 40:2; [M-Ac-H]-@8.28 0.7727 0.7388 1.0008 1.1914 1.3903 0.6398
PC 40:4; [M-Ac-H]-@7.45 1.2565 0.8503 0.7217 1.0147 0.8733 1.0356
PC 40:5; [M-Ac-H]-@7.22 0.8837 0.6216 1.1092 1.0003 1.2572 1.0765
PC 40:6; [M-Ac-H]-@6.81 0.9763 0.7141 0.9503 1.0619 0.9388 1.1722
PC 40:7; [M-Ac-H]-@6.36 1.0448 0.6856 0.9236 1.0862 1.0145 0.9852
PC 42:10; [M-Ac-H]-@5.85 1.1033 1.0799 0.5710 0.9922 0.9887 1.1244
PE 32:0; [M-H]-@6.81 0.9708 0.6344 0.6114 1.1296 1.6495 0.5897
PE 32:1; [M-H]-@6.31 0.8775 1.9570 0.7041 1.0568 1.0564 0.5336
PE 34:1; [M-H]-@6.94 0.8597 1.3014 0.9463 1.1184 0.8964 0.8493
PE 34:2; [M-H]-@6.48 0.6962 0.9381 1.3463 1.1670 1.0922 0.7337
PE 34:3; [M-H]-@6.05 0.8435 1.2739 0.8789 1.1522 0.8381 0.9137
PE 35:2; [M-H]-@6.76 0.8846 1.1691 1.1770 1.0976 1.0030 0.6923
PE 36:0; [M-H]-@7.95 1.1551 0.8587 0.8179 0.9036 1.3125 0.9213
PE 36:1; [M-H]-@7.53 0.8101 1.0939 1.2735 1.0659 0.8291 1.0255
PE 36:2; [M-H]-@7.07 0.7874 1.2829 1.1596 1.1165 0.8796 0.8371
PE 36:3; [M-H]-@6.62 0.8124 1.2854 1.1137 1.1079 0.8490 0.8833
PE 36:4; [M-H]-@6.28 1.0477 1.1355 0.9164 1.0826 0.8527 0.8564
PE 36:5; [M-H]-@6.02 0.7299 0.9481 0.6705 1.2387 0.9296 1.1279
PE 37:4; [M-H]-@6.72 1.0624 1.0514 0.8726 1.0449 0.9883 0.8745
PE 38:1; [M-H]-@7.53 0.9633 0.7620 1.2195 0.9490 0.8607 1.3196
PE 38:2; [M-H]-@6.95 1.1493 1.1159 0.9315 1.0720 0.6706 0.9307
PE 38:3; [M-H]-@7.31 0.9222 1.4404 0.9765 1.0887 1.0255 0.5932
PE 38:4; [M-H]-@7.02 1.1230 0.9849 0.9163 1.0985 0.7602 0.9119
PE 38:5; [M-H]-@6.57 0.9751 0.8953 0.9266 1.1439 0.7571 1.0590
PE 38:6; [M-H]-@6.20 0.7736 0.5820 1.3571 1.2189 0.8719 0.9598
PE 40:4; [M-H]-@7.50 1.0728 0.8970 0.8532 1.0930 0.8426 1.0098
PE 40:5; [M-H]-@7.25 0.9656 0.8366 0.9013 1.1071 1.0355 0.9353
PE 40:6; [M-H]-@6.97 0.9660 0.8917 0.8707 1.1723 0.7873 1.0143
PE 40:7; [M-H]-@6.47 0.8565 0.7967 1.2474 1.1322 0.8107 1.0428
PE 40:8; [M-H]-@6.04 0.9261 0.9564 0.9384 1.1063 0.7341 1.1866
PG 33:0; [M-H]-@6.10 1.0632 0.8507 1.5397 0.9685 0.6168 1.1121
PG 36:2; [M-H]-@6.08 1.0731 0.9201 0.8437 1.1102 0.8209 0.9820
PG 38:4; [M-H]-@6.07 0.8813 1.2635 0.8293 1.0104 1.1891 0.8832
PI 34:1; [M-H]-@5.71 0.9092 1.3112 0.6137 1.0798 1.2213 0.7635
PI 34:2; [M-H]-@5.26 1.1009 1.6470 0.6210 1.0127 0.8098 0.8474
PI 36:2; [M-H]-@5.92 1.1067 1.2968 0.8662 1.0312 0.7722 0.9042
PI 36:4; [M-H]-@5.26 1.3691 1.0533 0.6467 0.9823 0.7428 1.0063
PI 37:4; [M-H]-@5.59 1.0016 1.0155 1.0244 0.9868 0.9952 1.0068
PI 38:3; [M-H]-@6.10 1.3575 0.9212 0.8050 0.9798 0.7257 1.0272
PI 38:4; [M-H]-@5.88 1.3799 0.9023 0.6680 1.0690 0.6144 1.0045
PI 38:5; [M-H]-@5.40 0.9101 0.7927 0.7680 1.0938 0.9795 1.2142
PI 38:6; [M-H]-@5.14 0.8597 1.3156 0.8164 0.9600 0.9413 1.2510
PI 40:5; [M-H]-@5.99 1.2010 1.0545 0.7845 1.0356 0.7750 0.9813
PI 40:6; [M-H]-@5.83 0.9863 0.9268 0.7303 0.9841 0.9933 1.2908
plasmenyl-PE 32:1; [M-H]-@6.67 0.7811 0.8940 1.2341 1.1541 0.9596 0.8873
plasmenyl-PE 34:1; [M-H]-@7.27 0.9156 1.0740 0.9205 1.0866 0.7544 1.1596
plasmenyl-PE 34:2; [M-H]-@6.78 0.9252 1.1461 0.9237 1.1034 0.7343 1.0775
plasmenyl-PE 34:3; [M-H]-@6.42 0.6797 0.6316 1.6762 1.2160 0.6792 1.0388
plasmenyl-PE 36:1; [M-H]-@7.82 1.0214 1.0045 0.8380 1.0914 0.6771 1.1861
plasmenyl-PE 36:2; [M-H]-@7.36 0.9600 1.0774 0.8881 1.1248 0.7135 1.0714
plasmenyl-PE 36:3; [M-H]-@7.00 0.9546 1.1898 0.8492 1.1430 0.6749 1.0258
plasmenyl-PE 36:4; [M-H]-@6.73 1.0574 1.1402 0.7025 1.0758 0.5966 1.2548
plasmenyl-PE 36:5; [M-H]-@6.36 0.5845 0.6822 0.7575 1.3144 0.7225 1.4714
plasmenyl-PE 38:2; [M-H]-@7.97 1.0727 1.1452 0.8653 1.0577 0.9011 0.8603
plasmenyl-PE 38:3; [M-H]-@7.62 0.9614 0.8855 0.9947 1.0748 0.8010 1.1558
plasmenyl-PE 38:4; [M-H]-@7.31 1.0345 1.0982 0.8294 1.0449 0.6570 1.2405
plasmenyl-PE 38:5; [M-H]-@6.83 0.9904 1.1375 0.8079 1.0980 0.6649 1.1556
plasmenyl-PE 38:6; [M-H]-@6.62 1.0175 0.9277 0.8304 1.0677 0.7681 1.2117
plasmenyl-PE 40:3; [M-H]-@8.13 1.1268 0.9242 0.8459 1.0775 0.6985 1.1047
plasmenyl-PE 40:5; [M-H]-@7.35 1.0035 0.9076 0.7370 1.1368 0.7853 1.1279
plasmenyl-PE 40:6; [M-H]-@7.27 1.0521 0.9894 0.8439 1.0761 0.7758 1.0883
plasmenyl-PE 42:5; [M-H]-@7.95 0.9387 0.9125 0.6220 1.0870 0.8021 1.3870
Run Hierarchial cluster analysis on this study | Run Heatmap cluster analysis on this study

Factors:

F1visit:closeout
F2visit:initial visit
F3visit:intitial visit
F4visit:month 1
F5visit:month 12
F6visit:visit 1
  logo